ELUT
Elutia Inc.
There isn't enough reported data to score ELUT yet.
ELUT Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Weak | |
| Unavailable |
ELUT's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
ELUT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 0.8x | $0.94 | +7.2% |
| Current | 0.8x | $0.88 | — |
| Fair | 1x | $1.18 | +34% |
| Expensive | 1.2x | $1.43 | +62% |
Historical ranges are pointers, not guarantees.
ELUT's PE is 0.8x, but its earnings don't support one, so it isn't a reliable read right now.
ELUT Forward outlook
There aren't enough analyst estimates for ELUT to show an outlook.
ELUT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $1.15 | +$2.07 |
| Q2 2026 | $1.00 | +$2.06 |
| Q1 2026 | $0.91 | +$2.84 |
| Q4 2025 | $0.87 | +$3.34 |
| Q3 2025 | -$0.92 | +$1.65 |
| Q2 2025 | -$1.06 | +$1.75 |
| Q1 2025 | -$1.93 | +$0.40 |
| Q4 2024 | -$2.47 | -$0.40 |
ELUT has returned to profit: it earned $1.15 per share over the past year, after losing money the year before.
ELUT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.1M | -66% |
| Q2 2026 | $2.4M | -61% |
| Q1 2026 | $3.1M | -48% |
| Q4 2025 | $3.3M | -40% |
| Q3 2025 | $3.3M | -44% |
| Q2 2025 | $6.3M | -0.4% |
| Q1 2025 | $6M | -9.9% |
| Q4 2024 | $5.5M | -6.9% |
ELUT's revenue has slid since its 2023 peak: $1M last quarter, down 66% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -607% | -450 points |
| Q2 2026 | -328% | -170 points |
| Q1 2026 | -204% | -73 points |
| Q4 2025 | -201% | -46 points |
| Q3 2025 | -157% | +16 points |
| Q2 2025 | -158% | -22 points |
| Q1 2025 | -131% | -4.7 points |
| Q4 2024 | -154% | -9.4 points |
ELUT's operating margin was −607% last quarter, down 450 points from the same quarter a year ago, near the bottom of its range since 2020.
ELUT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$8.2M | -$4.7M |
| Q2 2026 | -$8.6M | -$210K |
| Q1 2026 | -$8.3M | +$869K |
| Q4 2025 | -$25.7M | -$13.3M |
| Q3 2025 | -$3.5M | +$457K |
| Q2 2025 | -$8.3M | -$4M |
| Q1 2025 | -$9.2M | -$6.5M |
| Q4 2024 | -$12.4M | -$3.3M |
ELUT has burned cash in almost every quarter: −$51M over the past year, against −$33M the year before.
ELUT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7.5% | +3.3M shares |
| 1 year | +1.2% | +581K shares |
| 3 years | +179% | +30.5M shares |
| 5 years | +364% | +37.3M shares |
ELUT has 48M diluted shares, up 1.2% from a year ago.
ELUT Net Leverage
ELUT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.8 | Neutral |
| Stochastic | 47.7 | Neutral |
ELUT's weekly RSI is 48 (neutral) and its Stochastic is 48 (neutral).
ELUT PE vs Healthcare Sector
| Metric | ELUT | Sector median | Relative |
|---|---|---|---|
| PE | 0.8x | 26x | 97% below |
| PE % | 3 | 33 | 30 pts below |
ELUT is trading at 0.8x earnings, a 97% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ELUT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.83 | 6% above |
| 20 week MA | $0.87 | 1.1% above |
| 50 week MA | $0.93 | 5.4% below |
| 100 week MA | $1.53 | 42% below |
| 200 week MA | $2.24 | 61% below |
ELUT has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 61% below its 200-week average.
ELUT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $13.5 | $12.6 | -7.2% |
| 2021 | $12.6 | $6.67 | -47% |
| 2022 | $6.67 | $4.10 | -39% |
| 2023 | $4.10 | $2.16 | -47% |
| 2024 | $2.16 | $3.94 | +82% |
| 2025 | $3.94 | $0.54 | -86% |
| 2026 YTD | $0.54 | $0.88 | +63% |
ELUT is up 63% so far in 2026, after finishing lower in five of the previous six years.